# GUIDANCE AND CRITERIA FOR APPLICATIONS FOR HUMBER & NORTH YORKSHIRE ICB FORMULARY

This document provides guidance on submitting an application to the HNY ICB formulary, and criteria against which the application will be considered.

## Criteria for consideration

The criteria below determine whether an application will be accepted for consideration by the HNY formulary group. Applications which do not meet these criteria will not be accepted.

Points one to three are the most applicable for considering the managed entry of new medicines.

1. The medicine will have a significant clinical and/or financial impact across the health economy of Humber and North Yorkshire, e.g.:
	* The target population is large, or is a significant subset of a larger population
	* The medicine is high cost

The impact may apply primary or secondary care alone or affect both sectors.

1. The medicine requires a managed and co-ordinated approach to introduction, e.g. to ensure equity of access or manage a safety issue.
2. The use of a medicine will significantly change the way that services are configured.
3. The use of the medicine is controversial. For example, the evidence base may not be fully developed and there may be a difference of clinical opinion as to the use of the medicine.
4. There is evidence of differing approaches to managing access to an existing medicine which is adversely affecting equity of access or consistency of service provision.
5. NICE guidance is either not planned or there will be significant delay before it is published, i.e. no technology appraisal is anticipated for at least 6 months.
6. A drug will not be considered by this group if it is considered to be an ‘exceptional circumstance’. These cases would be dealt with as currently.

## Completing an application form

Application forms are available from <https://humberandnorthyorkshire.org.uk/area-prescribing-committee-apc-documents-page/> and completed forms should be returned to hnyicb.mfg@nhs.net.

Please complete all sections clearly. Any missing or illegible information may delay the application. Ensure that you have:

1. Provided the rationale and evidence for the proposal, attaching any papers supporting the proposal to the form
2. Considered the formulary implications and place in therapy of the medicine, including a proposed RAG status. If there are implications for shared care then these should be clearly outlined.
3. Signed the completed proposal (electronic signatures are accepted), with a supporting signature from clinical or medical director, medicines optimisation lead, or other person with a similar position.

All paperwork must be submitted at least two weeks (14 calendar days) prior to the next meeting for consideration at that meeting. However the group cannot guarantee that the submission will be considered at the next meeting, due to existing work plans. The group usually meet every first Monday of each month.

The proposal will be considered by the group and a provisional recommendation will be made, which will then be opened for ICB-wide consultation.